Advertisement

Using In Vivo Biopanning for the Development of Radiation-Guided Drug Delivery Systems

  • Jerry J. Jaboin
  • Zhaozhong Han
  • Dennis E. HallahanEmail author
Protocol
Part of the Methods in Molecular Biology™ book series (MIMB, volume 542)

Summary

This chapter illustrates our protocol for in vivo biopanning using T7 bacteriophage libraries for the purpose of selecting recombinant peptides for the tumor-specific delivery of radiosensitizers to radiation-inducible antigens within tumor neovasculature. Our goal is to discover peptides binding within tumor vascular endothelium of irradiated tumors. We have previously demonstrated that tumor irradiation increases the spectrum of antigenic targets for drug delivery. To identify candidate peptides with the ability to bind radiation-induced antigens, we inject the phage peptide library intravenously into mice bearing irradiated GL261 and Lewis lung carcinoma (LLC) hind limb tumors. Phage are recovered from excised tumors, amplified, and readministered to mouse-bearing tumors for six total rounds. At least 50 bacterial colonies are selected from each of the tumor types, and prioritized. This prioritization is based on their relative concentrations in tumor versus normal tissues, and then assessment of dominant phage present in both tumor types. These phage are amplified, and the gene sequences determined to deduce the recombinant peptide product. Further prioritization is performed by fluorescence labeling of the selected phage, and injection into irradiated and mock-irradiated tumor-bearing mice for evaluation of in vivo targeting of the candidate phage/peptides.

Key Words

Biopanning drug delivery system mice phage display radiosensitization radiotherapy treatment-induced biomarker T7 bacteriophage tumor cells 

Notes

Acknowledgments

We thank Errki Ruoslahti (Burnham Institute for Medical Research, La Jolla, CA) for the peptide phage libraries, and Allie Fu, Ling Geng, Helina Onishko for their technical assistance. This work was supported by the US National Cancer Institutes grant R01-CA125757, the Ingram Charitable Fund, and the Vanderbilt–Ingram Cancer Center.

References

  1. 1.
    Geng, L., J. Tan, et al. (2004). “A specific antagonist of the p110delta catalytic component of phosphatidylinositol 3'-kinase, IC486068, enhances radiation-induced tumor vascular destruction.” Cancer Res 64(14): 4893–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Schueneman, A. J., E. Himmelfarb, et al. (2003). “SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models.” Cancer Res 63(14): 4009–16.PubMedGoogle Scholar
  3. 3.
    Han, Z., A. Fu, et al. (2008). “Noninvasive assessment of cancer response to therapy.” Nat Med 14(3): 343–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Duffy, A., J. Kortmansky, et al. (2008). “A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.” Ann Oncol 19(1): 86–91.PubMedCrossRefGoogle Scholar
  5. 5.
    Iannitti, D., T. Dipetrillo, et al. (2005). “Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study.” Am J Clin Oncol 28(6): 570–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Krishnan, S., P. D. Brown, et al. (2006). “Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.” Int J Radiat Oncol Biol Phys 65(4): 1192–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Camphausen, K., W. Burgan, et al. (2004). “Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.” Cancer Res 64(1): 316–21.PubMedCrossRefGoogle Scholar
  8. 8.
    Camphausen, K. and P. J. Tofilon (2007). “Inhibition of histone deacetylation: a strategy for tumor radiosensitization.” J Clin Oncol 25(26): 4051–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Cuneo, K. C., A. Fu, et al. (2007). “Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation.” Anticancer Drugs 18(7): 793–800.PubMedCrossRefGoogle Scholar
  10. 10.
    Geng, L., K. C. Cuneo, et al. (2006). “Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer.” Cancer Res 66(23): 11298–304.PubMedCrossRefGoogle Scholar
  11. 11.
    Jaboin, J., J. Wild, et al. (2002). “MS-27–275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.” Cancer Res 62(21): 6108–15.PubMedGoogle Scholar
  12. 12.
    Qian, D. Z., Y. F. Wei, et al. (2007). “Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.” Prostate 67(11): 1182–93.PubMedCrossRefGoogle Scholar
  13. 13.
    Colletier, P. J., F. Ashoori, et al. (2000). “Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation.” Int J Radiat Oncol Biol Phys 48(5): 1507–12.PubMedCrossRefGoogle Scholar
  14. 14.
    D'Avenia, P., A. Porrello, et al. (2006). “Tp53-gene transfer induces hypersensitivity to low doses of X-rays in glioblastoma cells: a strategy to convert a radio-resistant phenotype into a radiosensitive one.” Cancer Lett 231(1): 102–12.PubMedCrossRefGoogle Scholar
  15. 15.
    Pirollo, K. F., Z. Hao, et al. (1997). “p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy.” Oncogene 14(14): 1735–46.PubMedCrossRefGoogle Scholar
  16. 16.
    Atencio, I. A., M. Grace, et al. (2006). “Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial.” Cancer Gene Ther 13(2): 169–81.PubMedCrossRefGoogle Scholar
  17. 17.
    Fujiwara, T., N. Tanaka, et al. (2006). “Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer.” J Clin Oncol 24(11): 1689–99.PubMedCrossRefGoogle Scholar
  18. 18.
    Shimada, H., H. Matsubara, et al. (2006). “Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma.” Cancer Sci 97(6): 554–61.PubMedCrossRefGoogle Scholar
  19. 19.
    Tolcher, A. W., D. Hao, et al. (2006). “Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.” J Clin Oncol 24(13): 2052–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Swisher, S. G., J. A. Ajani, et al. (2003). “Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer.” Int J Radiat Oncol Biol Phys 57(1): 120–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Cook, T., Z. Wang, et al. (2004). “Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53.” Cancer Res 64(21): 8015–21.PubMedCrossRefGoogle Scholar
  22. 22.
    Hildebrandt, G., A. Radlingmayr, et al. (2003). “Low-dose radiotherapy (LD-RT) and the modulation of iNOS expression in adjuvant-induced arthritis in rats.” Int J Radiat Biol 79(12): 993–1001.PubMedCrossRefGoogle Scholar
  23. 23.
    Wang, Z., T. Cook, et al. (2004). “Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vascularity.” Cancer Res 64(4): 1386–95.PubMedCrossRefGoogle Scholar
  24. 24.
    Freeman, S. and J. M. Gardiner (1996). “Acyclic nucleosides as antiviral compounds.” Mol Biotechnol 5(2): 125–37.PubMedCrossRefGoogle Scholar
  25. 25.
    Germano, I. M., J. Fable, et al. (2003). “Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas.” J Neurooncol 65(3): 279–89.PubMedCrossRefGoogle Scholar
  26. 26.
    Klatzmann, D., C. A. Valery, et al. (1998). “A phase I/II study of herpes simplex virus type 1 thymidine kinase “suicide” gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma.” Hum Gene Ther 9(17): 2595–604.PubMedCrossRefGoogle Scholar
  27. 27.
    Rainov, N. G. (2000). “A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.” Hum Gene Ther 11(17): 2389–401.PubMedCrossRefGoogle Scholar
  28. 28.
    Freytag, S. O., H. Stricker, et al. (2003). “Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.” Cancer Res 63(21): 7497–506.PubMedGoogle Scholar
  29. 29.
    Chen, Y., T. DeWeese, et al. (2001). “CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity.” Cancer Res 61(14): 5453–60.PubMedGoogle Scholar
  30. 30.
    Dilley, J., S. Reddy, et al. (2005). “Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity.” Cancer Gene Ther 12(8): 715–22.PubMedCrossRefGoogle Scholar
  31. 31.
    DeWeese, T. L., H. van der Poel, et al. (2001). “A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.” Cancer Res 61(20): 7464–72.PubMedGoogle Scholar
  32. 32.
    Small, E. J., M. A. Carducci, et al. (2006). “A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.” Mol Ther 14(1): 107–17.PubMedCrossRefGoogle Scholar
  33. 33.
    Hallahan, D. E. (1996). “Introduction.” Semin Radiat Oncol 6(4): 243–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Hallahan, D. E., M. J. Staba-Hogan, et al. (1998). “X-ray-induced P-selectin localization to the lumen of tumor blood vessels.” Cancer Res 58(22): 5216–20.PubMedGoogle Scholar
  35. 35.
    Hallahan, D., E. T. Clark, et al. (1995). “E-selectin gene induction by ionizing radiation is independent of cytokine induction.” Biochem Biophys Res Commun 217(3): 784–95.PubMedCrossRefGoogle Scholar
  36. 36.
    Hallahan, D. E. (1996). “Radiation-mediated gene expression in the pathogenesis of the clinical radiation response.” Semin Radiat Oncol 6(4): 250–67.PubMedCrossRefGoogle Scholar
  37. 37.
    Hallahan, D. E., A. Y. Chen, et al. (1999). “Drug-radiation interactions in tumor blood vessels.” Oncology (Williston Park) 13(10 Suppl 5): 71–7.Google Scholar
  38. 38.
    Arap, W., R. Pasqualini, et al. (1998). “Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model.” Science 279(5349): 377–80.PubMedCrossRefGoogle Scholar
  39. 39.
    Rajotte, D. and E. Ruoslahti (1999). “Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display.” J Biol Chem 274(17): 11593–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Hallahan, D., L. Geng, et al. (2003). “Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels.” Cancer Cell 3: 63–74.PubMedCrossRefGoogle Scholar
  41. 41.
    Pasqualini, R. and E. Ruoslahti (1996). “Organ targeting in vivo using phage display peptide libraries.” Nature 380(6572): 364–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Smith, G. P. and V. A. Petrenko (1997). “Phage Display.” Chem Rev 97(2): 391–410.PubMedCrossRefGoogle Scholar
  43. 43.
    Staba, M. J., T. J. Wickham, et al. (2000). “Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models.” Cancer Gene Ther 7(1): 13–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Hariri, G., Y. Zhang, et al. (2008). “Radiation-guided P-selectin targeted antibody to lung cancer.” Ann Biomed Eng (in press).Google Scholar
  45. 45.
    Geng, L., E. Donnelly, et al. (2001). “Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.” Cancer Res 61(6): 2413–9.PubMedGoogle Scholar
  46. 46.
    Lu, B., L. Geng, et al. (2004). “Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium.” Int J Radiat Oncol Biol Phys 58(3): 844–50.PubMedCrossRefGoogle Scholar
  47. 47.
    Hallahan, D., J. Kuchibhotla, et al. (1996). “Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium.” Cancer Res 56(22): 5150–5.PubMedGoogle Scholar
  48. 48.
    Hallahan, D. E., L. Geng, et al. (2001). “Targeting drug delivery to radiation-induced neoantigens in tumor microvasculature.” J Control Rel 74(1–3): 183–91.CrossRefGoogle Scholar
  49. 49.
    Mehta, D. and A. B. Malik (2006). “Signaling mechanisms regulating endothelial permeability.” Physiol Rev 86(1): 279–367.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Jerry J. Jaboin
    • 1
  • Zhaozhong Han
    • 1
  • Dennis E. Hallahan
    • 1
    • 2
    Email author
  1. 1.Department of Radiation Oncology, Department of Biomedical Engineering, Department of Cancer Biology, School of MedicineVanderbilt UniversityNashvilleUSA
  2. 2.Vanderbilt-Ingram Cancer CenterNashvilleUSA

Personalised recommendations